Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ricacell
- Development stage
- Unknown
- Lead developer
- Juntendo University
- Modality
- Cell Therapies
- Administration
- Subcutaneous
01
Overview
Ricacell is an autologous cell therapy product developed by Ricacell Co., Ltd. for the treatment of alopecia, including androgenetic alopecia. The product is derived from the patient's own peripheral blood through a proprietary cell processing method. It is administered via subcutaneous injections into the scalp, where it is intended to stimulate hair growth and improve hair density by utilizing the regenerative properties of the processed autologous cells. A Phase 1/2 clinical trial (jRCTb030250640) has been conducted in Japan to evaluate its safety and preliminary efficacy in patients with alopecia.
- Brand names
- Ricacell
Beyond the preview
Go deeper on Ricacell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ricacell.